Dr. Byers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at HoustonFellowship, Medical Oncology, 2006 - 2009
Baylor College of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TX State Medical License 2006 - 2026
AL State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
- A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Publications & Presentations
PubMed
- Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans, Ming Zhao, Takanori Maejima
Clinical Cancer Research. 2024-11-25 - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.Alejandra G Serrano, Pedro Rocha, Cibelle Freitas Lima, Allison Stewart, Bingnan Zhang
NPJ Precision Oncology. 2024-11-19 - Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cance...Nagla Abdel Karim, Jieling Miao, Karen L Reckamp, Carl M Gay, Lauren A Byers
Journal of Thoracic Oncology. 2024-11-04
Journal Articles
- Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant CancersFaye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research
Press Mentions
Durvalumab Wins FDA Approval in Limited-Stage SCLCDecember 5th, 2024- How Are Targeted Therapies Used in Lung Cancer Treatment?July 30th, 2024
- Limited-Stage SCLC Gets a New Standard of Care with Consolidation DurvalumabJune 3rd, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
